Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of ...

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by Piper Sandler on March 14, 2025. The analyst firm set a price target for $6.00 expecting AKBA to rise to within 12 ...

March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with ... The Offering is being made only by means of a prospectus and prospectus ...

The offering is being conducted solely through a prospectus and prospectus supplement available on the SEC's website or from the underwriting firms. Thursday, AKBA closed at $2.04, marking a 28.17 ...

Akebia Therapeutics, Inc. has announced the commencement of an underwritten public offering of its common stock, with all shares being offered by the company itself. Akebia plans to give ...